8-K: Alzamend Neuro Secures $6 Million Financing, Faces Nasdaq Delisting Notice

Alzamend Neuro entered into a securities purchase agreement for up to $6 million in convertible preferred stock and warrants, while also receiving a notice of non-compliance from Nasdaq due to its stock price falling below $1.00.

Summary

• Alzamend Neuro has secured a financing agreement with Ault Lending, LLC, for up to $6 million through the sale of Series A convertible preferred stock and warrants.
• The initial closing involved the sale of 1,220 shares of preferred stock and warrants for 1,220,000 common shares, totaling $1.22 million, which was paid by canceling prior cash advances.
• The preferred stock has a stated value of $1,000 per share, does not accrue dividends, and is convertible into common stock at a price of $1.00 per share, subject to adjustments.
• Holders of the preferred stock have voting rights equivalent to common stock on an as-converted basis, with a voting floor price of $0.873.
• In the event of liquidation, preferred stockholders have a preferential right to receive the stated value before common stockholders.
• The warrants have an exercise price of $1.20 per share and become exercisable six months after issuance, expiring after five years.
• The agreement allows the purchaser to buy up to $2 million of preferred stock by March 31, 2024, and up to $4 million by March 31, 2025.
• Alzamend Neuro received a notice from Nasdaq for non-compliance with listing rules because its stock price closed below $1.00 for 30 consecutive days.
• The company has until July 30, 2024, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved, the company may be eligible for an additional 180-day period if it meets other listing requirements, potentially through a reverse stock split.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The financing agreement is a positive, but the delisting notice and potential dilution are significant negatives. The overall sentiment is cautiously negative.

Positives

• The financing agreement provides Alzamend Neuro with up to $6 million in capital.
• The initial closing provides immediate funding of $1.22 million.
• The preferred stock conversion price is set at $1.00, which could be beneficial if the stock price increases.
• The company has a period of time to regain compliance with Nasdaq listing rules.

Negatives

• The company's stock price has fallen below $1.00, triggering a Nasdaq delisting notice.
• The company may need to perform a reverse stock split to regain compliance.
• The financing involves the issuance of convertible preferred stock and warrants, which could dilute existing shareholders.
• The purchaser is an affiliate of the company, which may raise concerns about conflicts of interest.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• The conversion of preferred stock and exercise of warrants could significantly dilute existing shareholders.
• The company's ability to raise additional capital may be limited if it does not regain compliance with Nasdaq.
• The company's financial condition may be negatively impacted if it is unable to meet its obligations under the financing agreement.

Future Outlook

The company intends to actively monitor its stock price and evaluate options to regain compliance with Nasdaq listing rules. They also plan to file a proxy statement to obtain stockholder approval for the issuance of additional shares.

Industry Context

The financing agreement and delisting notice highlight the challenges faced by small biotech companies in maintaining financial stability and meeting exchange listing requirements. The need for capital is common, but the risk of delisting adds pressure.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a common method for biotech companies to raise capital, especially when facing financial challenges.
• The Nasdaq delisting notice is not uncommon for companies with low stock prices, and the 180-day compliance period is standard.
• The terms of the financing agreement, such as the conversion price and warrant exercise price, are typical for this type of transaction.
• Comparable companies facing similar challenges often explore options such as reverse stock splits or additional capital raises to maintain their listing.

Related Party Transactions

• The purchaser, Ault Lending, LLC, is an affiliate of the company.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of preferred stock and warrants.
• Shareholders face the risk of delisting if the company does not regain compliance with Nasdaq.
• The company's employees may be affected by the company's financial situation and potential delisting.
• The company's creditors may be impacted by the company's financial situation and potential delisting.

Next Steps

• The company will monitor its stock price to regain compliance with Nasdaq listing rules.
• The company will file a proxy statement to obtain stockholder approval for the issuance of additional shares.
• The company may evaluate options such as a reverse stock split to regain compliance.

Key Dates

Keywords

Alzamend Neuro, financing, convertible preferred stock, warrants, Nasdaq, delisting, compliance, stock price, Ault Lending, capital raise